Douglas Hunt — Senior Vice President of Regulatory Affairs at Puma Biotechnology

Mr. Douglas Hunt, FRAPS, has been Senior Vice President of Regulatory Affairs at Puma Biotechnology, Inc. since January 2, 2018. Mr. Hunt as over 25 years of regulatory affairs experience and was regulatory affairs consultant to Puma Biotechnology since February 2017. Mr. Hunt served as Vice President of Regulatory Affairs and Quality Assurance at ArmaGen, Inc. from March 2015 to December 2017. Prior to joining ArmaGen in May 2015, he served as Vice President Global Regulatory Affairs of Baxter Bioscience from March 2008 to March 2015. Prior to that, Mr. Hunt worked for Amgen Inc. from June 2000 to March 2008 in various positions, including as Executive Director, Therapeutic Area Head (Oncology) and Executive Director, Therapeutic Area Head (Bone/Oncology), Global Regulatory Affairs and Safety. Prior to that, he served as Senior Director Global Regulatory Affairs at Quintiles. During his tenure at Baxter and Amgen, he led teams that supported global approvals of OBIZUR, RIXUBIS, HYQVIA, PreFLUCEL, NPLATE, ARANESP, ENBREL and NEULASTA. Prior to Quintiles, Mr. Hunt received his B.Sc. in biological sciences from Portsmouth University (UK).